Mentari Therapeutics, Inc. has filed unaudited financial statements for the period ending September 30, 2026, following the completion of a business combination with InMed Pharmaceuticals Inc. The merger closed on November 6, 2026, resulting in the combined entity operating under the name Mentari Therapeutics, Inc.

According to the unaudited condensed consolidated balance sheets, the company reported total assets of $52.44 million as of September 30, 2026. This figure includes $45.79 million in cash and cash equivalents and $49.18 million in current assets. The company’s liabilities totaled $78.61 million, primarily consisting of a $49.98 million note payable to a related party and $26.41 million in current liabilities, including accounts payable and accrued expenses.

The unaudited condensed consolidated statements of operations show a net loss of $32.24 million for the three months ended September 30, 2026. This compares to a net loss of $6.61 million for the same period in the prior year. Research and development expenses for the recent quarter were reported at $28.44 million, while general and administrative expenses totaled $2.77 million.

The company’s cash flows for the nine months ended September 30, 2026, showed a net cash used in operating activities of $47.97 million. This was partially offset by $47.51 million in net cash provided by financing activities, which included proceeds from the issuance of Series A convertible preferred stock and a related-party note payable.

Mentari’s pipeline includes MT-001, an anti-PACAP monoclonal antibody; MT-002, an anti-PACAP and anti-CGRP bispecific antibody; MT-003, an anti-CGRP half-life extended antibody; and MT-004 and MT-005, antibodies targeting novel, undisclosed targets for migraine prevention.